Summary of Conference Call on Experimental Monkey Supply and Demand Industry Overview - The report focuses on the experimental monkey supply and demand dynamics, particularly in the context of preclinical Contract Research Organizations (CROs) [1][2] - The global supply of experimental monkeys is tight, with a projected shortfall of nearly 10,000 monkeys in China and 20,000 to 30,000 in the U.S. by 2024 [1][4] Key Points and Arguments Supply Constraints - China's experimental monkey population is aging, with 80% of breeding females over 8 years old in 2023, severely limiting breeding capacity [1][6] - The high prices from 2019 to 2022 led to significant loss of breeding monkeys, and the long breeding cycle of the species further complicates supply recovery [1][6] - Importing monkeys from overseas faces multiple constraints, including strict approvals and complex quarantine requirements, which hinder short-term improvements in supply [1][7] Demand Drivers - The demand for experimental monkeys is expected to grow significantly due to improved investment in innovative drugs, with projections of 45,000 to 50,000 monkeys needed in China from 2026 to 2028 [1][11] - The increase in IND (Investigational New Drug) applications is anticipated to continue, reflecting a recovery in preclinical safety evaluation demand [1][11] Price Trends - Monkey prices are expected to rise again, potentially reaching previous highs of over 200,000 yuan per monkey by 2026-2028 due to the expanding supply-demand gap [1][12][13] - The price fluctuations have historically ranged from 3,000 yuan to over 200,000 yuan, with recent trends indicating a recovery from lows of 80,000 to 100,000 yuan [1][4] Impact on CROs - The profitability of preclinical CROs is expected to improve as monkey prices rise, with net profit margins projected to rebound from negative values to around 10% by 2025 [1][14] - The fair value changes related to monkey assets will significantly impact companies like Zhaoyan New Drug, which is expected to see a profit contribution of approximately 450 to 500 million yuan from fair value changes in 2025 [1][15][16] Additional Important Insights - The report highlights the potential impact of U.S. trade changes with Cambodia, which could further strain China's monkey supply as U.S. demand may siphon off available resources [1][9] - The analysis indicates that unless there is a large-scale opening of monkey imports, the supply issues in China will persist through 2026-2027 [1][10] - The report emphasizes the importance of monitoring the performance of key CROs such as WuXi AppTec, Kanglong Chemical, and Medpace, as they are expected to benefit from the evolving market dynamics [1][17]

Group 1 - The core viewpoint of the article highlights the significant increase in the stock price of Zhaoyan New Drug (06127), which rose by 7.1% to HKD 18.56, with a trading volume of HKD 42.5682 million [1] - The price of experimental monkeys has surged, with the cost for 3-5 year old macaques reaching HKD 140,000 each, indicating a supply-demand imbalance in the market [1] - Zhaoyan New Drug is identified as the largest supplier of experimental monkeys globally, positioning the company favorably in a market experiencing increased demand due to a resurgence in new drug development [1] Group 2 - According to estimates from Founder Securities, the supply of experimental monkeys is projected to be around 49,000 to 52,400 annually from 2025 to 2027, while the demand is expected to be between 51,300 and 62,600 annually [1] - The short-term outlook suggests that the demand for experimental monkeys will increase due to the recovery in new drug research and development, while improvements on the supply side are expected to be challenging [1] - The ongoing supply-demand gap in the experimental monkey market is likely to widen in the near term, driven by the factors mentioned above [1]